Midgard Science
SB

Samsung Biologics

Incheon, South Korea samsungbiologics.com From their website, Nov 2026

  • GMP

Work here? Claim this listing

About

Samsung Biologics is a biologics CDMO that provides development, manufacturing, and analytical testing services for biopharmaceutical companies. It supports programs from late discovery and cell line development through commercial drug substance, drug product, and aseptic fill-finish manufacturing from sites in Incheon, South Korea, and Rockville, Maryland.

Services

  • Organoid Services

    Uses patient-derived tumor organoids, AI-based predictive analysis, and multi-omics data for precision drug screening, target identification, and translational research.

  • Late Discovery Services

    Provides proprietary platforms to accelerate transition from research to development, including bispecific antibody discovery and developability assessment.

  • Cell Line Development

    Develops cell lines for biologics and complex molecules using proprietary CHO platforms and screening workflows to support IND/IMPD submissions.

    Cell line development

  • Process Development

    Offers phase-appropriate upstream, downstream, and formulation development using QbD, design-of-experiment methods, and in-house analytics.

  • Analytical Development

    Develops analytical methods and supports characterization, comparability, stability, and method transfer for biologics programs.

  • Non-GMP and CGMP Manufacturing

    Manufactures preclinical, clinical, and commercial biologics with non-GMP and CGMP workflows across multiple batch sizes.

    CDMO: development & manufacturing

  • Drug Substance Manufacturing

    Provides clinical-to-commercial drug substance manufacturing with single-use and stainless-steel bioreactor options.

    CDMO: development & manufacturing

  • Drug Product Manufacturing

    Provides aseptic fill-finish drug product manufacturing for biologics and small molecules, including vials and prefilled syringes.

    CDMO: development & manufacturing

8 more services
  • Bioconjugation Development and Manufacturing
  • mRNA Manufacturing and Development Services
  • Analytical Testing Services
  • Quality and GMP Services
  • Non-GMP / CGMP Manufacturing
  • Aseptic Fill-Finish
  • Bioconjugation
  • mRNA Services
Turnaround
30 days to 285 days
What to send
  • 80 mg minimum material for DEVELOPICK®
  • Patient tumor tissue for organoid generation
  • Parental antibody sequences for S-DUAL®
Minimums and prices
Competitive pricing for S-DUAL® (no amount stated)

Capabilities

Assays and studies
  • Process development
  • Analytical development
  • mRNA
  • ADCs
  • Fill-finish
  • Peptides
24 more
  • CHO
  • LNP
  • Lyophilization
  • qPCR
  • Protein concentration
  • Titer
  • N-glycan profile
  • Peptide mapping
  • iCIEF
  • Flow cytometry
  • Bioassay
  • Purity
  • CE-SDS
  • Residual host cell DNA
  • Residual host cell protein
  • Residual protein A
  • Potency
  • Sterility
  • Endotoxin
  • Precision drug screening
  • Developability assessment
  • Analytical testing
  • Mycoplasma test
  • In vitro virus test
Scale and capacity
  • 845 kL total capacity
  • 1,000 L to 15,000 L bioreactor capacity
  • 0.1 L to 200 L single-use mRNA batch capacity
  • 5 L to 2,500 L batch sizes for drug product
  • Up to 350,000 vials per day
  • Up to 500 L train for bioconjugation
10 more
  • 50 L and 200 L single-use bioreactors
  • 2R-50R aseptic vial filling for preclinical studies
  • 5–15 kL drug substance scale
  • ≤2 kL small-scale drug substance
  • Bio Campus II scheduled for completion in 2032
  • 50 L and 200 L single-use bioreactor manufacturing
  • 1 kL manufacturing support
  • 5–15 kL large-scale drug substance
  • 2R-50R aseptic vial filling
  • Bio Campus II completion scheduled for 2032
Therapeutic areas
  • Oncology
  • Precision oncology

Instruments and platforms

  • Ambr 15
  • 2L STR
  • qPCR
  • ELISA
  • Flow cytometry
  • Octet® HTX
  • AKTA
  • UF/DF equipment

Modalities and species

Modalities
  • Small molecule
  • Antibody
  • Bispecific
  • ADC
  • Peptide
  • Oligonucleotide
3 more
  • mRNA
  • Recombinant protein
  • LNP / formulation
Species and models
  • Patient-derived tumor organoids
  • 3D tumor models
  • Colorectal cancer
  • Lung cancer
  • Liver cancer
  • Gastric cancer
8 more
  • Breast cancer
  • CHO cell lines
  • CHOZN cell lines
  • MRC-5
  • Vero
  • CHO-K1
  • A9
  • NIH3T3

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

    Scope: biologics manufacturing and fill-finish

Company

Type
CRDMO
Founded
2011
Size
1001-5000 employees

Locations

Based in
Incheon, South Korea
Sites
  • Rockville, United States
  • Yeonsu-gu, Republic of Korea
Serves
Global, Europe, Asia, U.S., Asia-Pacific

Public records

FDA drug establishment registration
3010479596 · ANALYSIS; API MANUFACTURE; LABEL; MANUFACTURE; PACK source
Wikidata
1,532 · Q16767532 source

Similar labs